Cargando…

Sirukumab for rheumatoid arthritis: the phase III SIRROUND-D study

OBJECTIVES: Interleukin-6 (IL-6) is implicated in rheumatoid arthritis (RA) pathophysiology. Unlike IL-6 receptor inhibitors, sirukumab is a human monoclonal antibody that selectively binds to the IL-6 cytokine. The phase III, multicentre, randomised, double-blind, placebo-controlled, parallel-group...

Descripción completa

Detalles Bibliográficos
Autores principales:	Takeuchi, Tsutomu, Thorne, Carter, Karpouzas, George, Sheng, Shihong, Xu, Weichun, Rao, Ravi, Fei, Kaiyin, Hsu, Benjamin, Tak, Paul P
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2017
Materias:	Clinical and Epidemiological Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5705845/ https://www.ncbi.nlm.nih.gov/pubmed/28855173 http://dx.doi.org/10.1136/annrheumdis-2017-211328

Ejemplares similares

Investigating sirukumab for rheumatoid arthritis: 2-year results from the phase III SIRROUND-D study
por: Thorne, Carter, et al.
Publicado: (2018)

Long-term safety and efficacy of sirukumab for patients with rheumatoid arthritis who previously received sirukumab in randomised controlled trials (SIRROUND-LTE)
por: Aletaha, Daniel, et al.
Publicado: (2021)

Sirukumab, a human anti-interleukin-6 monoclonal antibody: a randomised, 2-part (proof-of-concept and dose-finding), phase II study in patients with active rheumatoid arthritis despite methotrexate therapy
por: Smolen, Josef S, et al.
Publicado: (2014)

Spotlight on sirukumab for the treatment of rheumatoid arthritis: the evidence to date
por: Lazzerini, Pietro Enea, et al.
Publicado: (2016)

Sirukumab in rheumatoid arthritis refractory to sulfasalazine or methotrexate: a randomized phase 3 safety and efficacy study in Japanese patients
por: Takeuchi, Tsutomu, et al.
Publicado: (2018)

Sirukumab: A Potential Treatment for Mood Disorders?
por: Zhou, Aileen J., et al.
Publicado: (2016)

Postmarketing surveillance of tocilizumab for rheumatoid arthritis in Japan: interim analysis of 3881 patients
por: Koike, Takao, et al.
Publicado: (2011)

Baseline tumour necrosis factor alpha levels predict the necessity for dose escalation of infliximab therapy in patients with rheumatoid arthritis
por: Takeuchi, Tsutomu, et al.
Publicado: (2011)

Fcγ receptor IIIb polymorphism and use of glucocorticoids at baseline are associated with infusion reactions to infliximab in patients with rheumatoid arthritis
por: Okuyama, Ayumi, et al.
Publicado: (2010)

Two-dose COVID-19 vaccination and possible arthritis flare among patients with rheumatoid arthritis in Hong Kong
por: Li, Xue, et al.
Publicado: (2022)

Golimumab in combination with methotrexate in Japanese patients with active rheumatoid arthritis: results of the GO-FORTH study
por: Tanaka, Yoshiya, et al.
Publicado: (2011)

Risk of obstructive sleep apnoea in patients with rheumatoid arthritis: a nationwide population-based retrospective cohort study
por: Shen, Te-Chun, et al.
Publicado: (2016)

Quality of life, sleep and rheumatoid arthritis (QUASAR): a protocol for a prospective UK mHealth study to investigate the relationship between sleep and quality of life in adults with rheumatoid arthritis
por: Druce, Katie L, et al.
Publicado: (2018)

Exploratory analyses of the association of MRI with clinical, laboratory and radiographic findings in patients with rheumatoid arthritis
por: Emery, Paul, et al.
Publicado: (2011)

The Canadian Methotrexate and Etanercept Outcome Study: a randomised trial of discontinuing versus continuing methotrexate after 6 months of etanercept and methotrexate therapy in rheumatoid arthritis
por: Pope, Janet E, et al.
Publicado: (2014)

Smoking and overweight determine the likelihood of developing rheumatoid arthritis
por: de Hair, Maria J H, et al.
Publicado: (2013)

A Multicentre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Sirukumab in the Treatment of Giant Cell Arteritis
por: Schmidt, Wolfgang A., et al.
Publicado: (2020)

Assessment by MRI of inflammation and damage in rheumatoid arthritis patients with methotrexate inadequate response receiving golimumab: results of the GO-FORWARD trial
por: Conaghan, Philip G, et al.
Publicado: (2011)

Treating Rheumatoid Arthritis to Target: multinational recommendations assessment questionnaire
por: Haraoui, Boulos, et al.
Publicado: (2011)

Identification and Treatment Optimization of Comorbid Depression in Rheumatoid Arthritis
por: Withers, Mellissa H., et al.
Publicado: (2017)

Effect of denosumab on Japanese patients with rheumatoid arthritis: a dose–response study of AMG 162 (Denosumab) in patients with RheumatoId arthritis on methotrexate to Validate inhibitory effect on bone Erosion (DRIVE)—a 12-month, multicentre, randomised, double-blind, placebo-controlled, phase II clinical trial
por: Takeuchi, Tsutomu, et al.
Publicado: (2016)

Comorbidity burden in the first three years after diagnosis in patients with rheumatoid arthritis, psoriatic arthritis or spondyloarthritis: a general practice registry-based study
por: Stouten, Veerle, et al.
Publicado: (2021)

Overview of biotherapy in rheumatoid arthritis (RA)
por: Takeuchi, Tsutomu, et al.
Publicado: (2012)

Interstitial lung disease in rheumatoid arthritis: incidence, prevalence and related drug prescriptions between 2007 and 2020
por: Albrecht, Katinka, et al.
Publicado: (2023)

Safety and efficacy of ocrelizumab in combination with methotrexate in MTX-naive subjects with rheumatoid arthritis: the phase III FILM trial
por: Stohl, William, et al.
Publicado: (2012)

Efficacy and safety of the oral Janus kinase inhibitor peficitinib (ASP015K) monotherapy in patients with moderate to severe rheumatoid arthritis in Japan: a 12-week, randomised, double-blind, placebo-controlled phase IIb study
por: Takeuchi, Tsutomu, et al.
Publicado: (2016)

Adalimumab, a human anti-TNF monoclonal antibody, outcome study for the prevention of joint damage in Japanese patients with early rheumatoid arthritis: the HOPEFUL 1 study
por: Takeuchi, Tsutomu, et al.
Publicado: (2014)

TWEAK and its receptor Fn14 in the synovium of patients with rheumatoid arthritis compared to psoriatic arthritis and its response to tumour necrosis factor blockade
por: van Kuijk, A W R, et al.
Publicado: (2009)

Biologic refractory disease in rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis
por: Kearsley-Fleet, Lianne, et al.
Publicado: (2018)

Clinical benefit of 1-year certolizumab pegol (CZP) add-on therapy to methotrexate treatment in patients with early rheumatoid arthritis was observed following CZP discontinuation: 2-year results of the C-OPERA study, a phase III randomised trial
por: Atsumi, Tatsuya, et al.
Publicado: (2017)

Antirheumatic treatment, disease activity and risk of Staphylococcus aureus bacteraemia in rheumatoid arthritis: a nationwide nested case–control study
por: Dieperink, Sabine Sparre, et al.
Publicado: (2022)

What is the future of CCR5 antagonists in rheumatoid arthritis?
por: Takeuchi, Tsutomu, et al.
Publicado: (2012)

Overlap of disease susceptibility loci for rheumatoid arthritis and juvenile idiopathic arthritis
por: Hinks, Anne, et al.
Publicado: (2010)

15017 Monoclonal antibody use in rheumatoid arthritis: an evaluation of medical expenditure
por: Kelly, Robert A., et al.
Publicado: (2021)

Drug-specific risk and characteristics of lupus and vasculitis-like events in patients with rheumatoid arthritis treated with TNFi: results from BSRBR-RA
por: Jani, Meghna, et al.
Publicado: (2017)

The association between gastro-oesophageal reflux disease and subsequent rheumatoid arthritis occurrence: a nested case–control study from Taiwan
por: Lin, Herng-Ching, et al.
Publicado: (2017)

Efficacy and safety of mavrilimumab in subjects with rheumatoid arthritis
por: Burmester, Gerd R, et al.
Publicado: (2013)

Mortality in patients with rheumatoid arthritis: a 15-year prospective cohort study
por: van den Hoek, J., et al.
Publicado: (2016)

Bone mineral density in rheumatoid arthritis patients 1 year after adalimumab therapy: arrest of bone loss
por: Wijbrandts, C A, et al.
Publicado: (2008)

Continued inhibition of structural damage over 2 years in patients with rheumatoid arthritis treated with rituximab in combination with methotrexate
por: Cohen, Stanley B, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_75pphubtvl88akp50l3keh731q